Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | PGD | P52209 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL5875445 | 1.00 | TSHR (0.71) | TSHRTP53NFKB1CYP2C19CYP2C9 | |
| Cadaverine Tartrate SCHEMBL2216947 | 0.89 | TSHR (0.91) | TSHRTP53NFKB1CYP2C19CYP2C9 | |
| Cadaverine Tartrate SCHEMBL8945831 | 0.85 | TSHR (0.83) | TSHRTP53NFKB1CYP2C19CYP2C9 | |
| Cadaverine Tartrate SCHEMBL4778934 | 0.85 | TSHR (0.83) | TSHRTP53NFKB1CYP2C19CYP2C9 | |
| Tartaric Acid SCHEMBL5762 | 0.84 | TSHR (1.00) | TSHRTP53NFKB1CYP2C19CYP2C9 | |
| Cadaverine Tartrate SCHEMBL1062721 | 0.84 | TSHR (1.00) | TSHRTP53NFKB1CYP2C19CYP2C9 | |
| Cadaverine Tartrate SCHEMBL848 | 0.84 | TSHR (1.00) | TSHRTP53NFKB1CYP2C19CYP2C9 | |
| Cadaverine Tartrate SCHEMBL116846 | 0.84 | TSHR (1.00) | TSHRTP53NFKB1CYP2C19CYP2C9 | |
| Cadaverine Tartrate SCHEMBL1431070 | 0.84 | TSHR (1.00) | TSHRTP53NFKB1CYP2C19CYP2C9 | |
| Cadaverine Tartrate SCHEMBL31427568 | 0.84 | TSHR (1.00) | TSHRTP53NFKB1CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109438268-B | Choline bitartrate and preparation method thereof | 济南蓬勃生物技术有限公司 | 2021-08-03 | — | — | CN | claimed |
| CN-119462685-A | Arteannuin derivative and application thereof in treating cerebral apoplexy | 上海英诺富成生物科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-109438268-B | Choline bitartrate and preparation method thereof | 济南蓬勃生物技术有限公司 | 2021-08-03 | — | — | CN | disclosed |
| CN-109438268-B | Choline bitartrate and preparation method thereof | 济南蓬勃生物技术有限公司 | 2021-08-03 | — | — | CN | disclosed |
| US-20200179254-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | HENKEL AG & CO. KGAA (DE) | 2020-06-11 | — | — | US | disclosed |
| WO-2020078408-A1 | CHOLINE BITARTRATE AND PREPARATION METHOD THEREFOR | 济南蓬勃生物技术有限公司 | 2020-04-23 | — | — | WO | disclosed |
| US-20190240129-A1 | CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | HENKEL AG & CO. KGAA (DE) | 2019-08-08 | — | — | US | disclosed |
| EP-3518878-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | Henkel AG & Co. KGaA (DE) | 2019-08-07 | — | — | EP | disclosed |
| US-20190216703-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | HENKEL AG & CO. KGAA (DE) | 2019-07-18 | — | — | US | disclosed |
| US-20190216714-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | HENKEL AG & CO. KGAA (DE) | 2019-07-18 | — | — | US | disclosed |
| US-7128976-B2 | Composition for film formation, method of film formation, and silica-based film | JSR CORPORATION (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20030091838-A1 | Composition for film formation, method of film formation, and silica-based film | JSR CORPORATION (JP) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240129-A1 | CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | KRT18, CUTA, S100A10 | TSHR 3146/4885TP53 2105/4885NFKB1 3643/4885 |
| US-20190216703-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | KRT18, SRRM2, IK | TSHR 1850/4885TP53 2548/4885NFKB1 3996/4885 |
| US-20190216714-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | KRT18, CD44, PCNA | TSHR 3345/4885TP53 1209/4885NFKB1 2864/4885 |
| US-20200179254-A1 | IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION | KRT18, CUTA, DSG1 | TSHR 2235/4885TP53 1442/4885NFKB1 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.